These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27859668)

  • 1. The effects of olanzapine treatment on brain regional glucose metabolism in neuroleptic-naive first-episode schizophrenic patients.
    Yoshimuta H; Nakamura M; Kanda E; Fujita S; Takeuchi K; Fujimoto T; Nakabeppu Y; Akasaki Y; Sano A
    Hum Psychopharmacol; 2016 Nov; 31(6):419-426. PubMed ID: 27859668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia.
    Molina V; Gispert JD; Reig S; Pascau J; Martínez R; Sanz J; Palomo T; Desco M
    Int Clin Psychopharmacol; 2005 Jan; 20(1):13-8. PubMed ID: 15602110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia.
    Wang CH; Li Y; Yang J; Su LY; Geng YG; Li H; Wang JK; Mu JL
    Schizophr Res; 2013 Mar; 144(1-3):129-35. PubMed ID: 23352776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early effects of treatment on regional cerebral blood flow in first episode schizophrenia patients evaluated with 99Tc-ECD-SPECT.
    Novak B; Milcinski M; Grmek M; Kocmur M
    Neuro Endocrinol Lett; 2005 Dec; 26(6):685-9. PubMed ID: 16380684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study.
    Lui S; Deng W; Huang X; Jiang L; Ma X; Chen H; Zhang T; Li X; Li D; Zou L; Tang H; Zhou XJ; Mechelli A; Collier DA; Sweeney JA; Li T; Gong Q
    Am J Psychiatry; 2009 Feb; 166(2):196-205. PubMed ID: 18981063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine modulation of long- and short-range functional connectivity in the resting brain in a sample of patients with schizophrenia.
    Guo W; Liu F; Chen J; Wu R; Li L; Zhang Z; Zhao J
    Eur Neuropsychopharmacol; 2017 Jan; 27(1):48-58. PubMed ID: 27887859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
    Konarzewska B; Waszkiewicz N; Galińska B; Szulc A
    Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300.
    Higuchi Y; Sumiyoshi T; Kawasaki Y; Matsui M; Arai H; Kurachi M
    Schizophr Res; 2008 Apr; 101(1-3):320-30. PubMed ID: 18321680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics.
    Sabri O; Erkwoh R; Schreckenberger M; Cremerius U; Schulz G; Dickmann C; Kaiser HJ; Steinmeyer EM; Sass H; Buell U
    J Nucl Med; 1997 Feb; 38(2):181-8. PubMed ID: 9025731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct effects of duration of untreated psychosis on brain cortical activities in different treatment phases of schizophrenia: a multi-channel near-infrared spectroscopy study.
    Chou PH; Koike S; Nishimura Y; Kawasaki S; Satomura Y; Kinoshita A; Takizawa R; Kasai K
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():63-9. PubMed ID: 24275075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients.
    Siegel BV; Buchsbaum MS; Bunney WE; Gottschalk LA; Haier RJ; Lohr JB; Lottenberg S; Najafi A; Nuechterlein KH; Potkin SG
    Am J Psychiatry; 1993 Sep; 150(9):1325-36. PubMed ID: 8352343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12.
    Smesny S; Kunstmann C; Kunstmann S; Willhardt I; Lasch J; Yotter RA; Proffitt TM; Kerr M; Marculev C; Milleit B; Milleit C; Nenadic I; Amminger P; McGorry PD; Sauer H; Berger GE
    World J Biol Psychiatry; 2011 Dec; 12(8):598-607. PubMed ID: 21143005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic drug effects on brain morphology in first-episode psychosis.
    Lieberman JA; Tollefson GD; Charles C; Zipursky R; Sharma T; Kahn RS; Keefe RS; Green AI; Gur RE; McEvoy J; Perkins D; Hamer RM; Gu H; Tohen M;
    Arch Gen Psychiatry; 2005 Apr; 62(4):361-70. PubMed ID: 15809403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrical brain activity and response to olanzapine in schizophrenia: a study with LORETA images of P300.
    Sumiyoshi T; Higuchi Y; Kawasaki Y; Matsui M; Kato K; Yuuki H; Arai H; Kurachi M
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1299-303. PubMed ID: 16769169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia.
    Tislerova B; Brunovsky M; Horacek J; Novak T; Kopecek M; Mohr P; Krajca V
    Neuropsychobiology; 2008; 58(1):1-10. PubMed ID: 18781085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
    Volavka J; Czobor P; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
    J Clin Psychiatry; 2011 Jul; 72(7):955-61. PubMed ID: 21824456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders.
    Korostenskaja M; Dapsys K; Siurkute A; Maciulis V; Ruksenas O; Kähkönen S
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):543-8. PubMed ID: 15866356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.
    de Jesus Mari J; Lima MS; Costa AN; Alexandrino N; Rodrigues-Filho S; de Oliveira IR; Tollefson GD
    Eur Arch Psychiatry Clin Neurosci; 2004 Dec; 254(6):356-61. PubMed ID: 15538607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.
    Bartlett EJ; Brodie JD; Simkowitz P; Schlösser R; Dewey SL; Lindenmayer JP; Rusinek H; Wolkin A; Cancro R; Schiffer W
    Am J Psychiatry; 1998 Mar; 155(3):337-43. PubMed ID: 9501742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.